Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: Data from a real-world prospective cohort study
RMD Open 2025;11:e006333 Doi: 10.1136/rmdopen-2025-006333
Temiz et al. showed that this long-term data provides strong evidence that BARI maintains its clinical efficacy, drug survival and acceptable safety profile as monotherapy over several years in a real-world setting. Authors evaluated the long-term efficacy, drug survival and safety of BARI monotherapy versus combination therapy in a prospective cohort of patients with RA.
The similar outcomes observed for monotherapy and combination indicate that BARI may be used effectively as monotherapy in patients with RA for whom MTX is not suitable or tolerated. This study reports the use of BARI as monotherapy and underlines the
long-term safety of treatment with BARI in patients with RA.
Keywords:
